No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
09939 KINTOR PHARMA-B
- 0.830
- -0.020-2.35%
Trading Apr 19 15:51 CST
371.42MMarket Cap-317P/E (TTM)
0.880High0.810Low572.50KVolume0.850Open0.850Pre Close479.41KTurnover0.13%Turnover RatioLossP/E (Static)447.50MShares5.83052wk High0.73P/B371.42MFloat Cap0.81052wk Low--Dividend TTM447.50MShs Float89.000Historical High--Dividend LFY8.24%Amplitude0.810Historical Low0.837Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Develop the pharmaceutical industry's 2023 performance: explore Pico's multi-channel commercialization path and dig deeper into multi-pipeline R&D and commercial value
SUZHOU, March 29, 2024/PRNewswire/ -- On March 29, 2024, Beijing time, Kaituo Pharmaceutical (stock code: 9939.HK), a biopharmaceutical company focused on the development and industrialization of potential pioneers and best-in-class innovative drugs, announced recent business highlights and annual results for the year ending December 31, 2023. 2023 Annual Results Overview Business Overview Pico Dual Core Products Global Clinical Research and Development Continues to Advance Multiple Pipelines Reveal the Value of R&D and Commercial Cooperation Multiple Research Results Selected for Important Academic Conferences and Financial Overview Funding in Core Journals
Kaituo Pharmaceutical-B (09939) announced its 2023 annual results, with a net loss of 1.06 billion yuan, an increase of 11.2% over the previous year
Kaituo Pharmaceutical-B (09939) announced the results for the year ended December 31, 2023, and the Group has not approved the entry...
KINTOR PHARMA-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Kaituo Pharmaceutical-B (09939.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 15 | Kaituo Pharmaceutical-B (09939.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
KINTOR PHARMA-B: DATE OF BOARD MEETING
Kaituo Pharmaceutical-B (09939) published research results on c-MYC-targeting molecular gum compounds in the Nature sub-journal
The article mainly analyzes the mechanism of action of MYC in inducing resistance to CDK4/6 inhibitors by promoting PRB1 degradation, and suggests that the c-Myc degrading agent a80.2hcl can enhance the therapeutic effect of CDK4/6 inhibitors.
Comments
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
$KINTOR PHARMA-B(09939.HK$
With the opening up, it is inevitable the Covid cases will jump into hundreds of thousand. This is where this covid treatment drug will greatly benefit along with some of the other approved Covid treatments
With the opening up, it is inevitable the Covid cases will jump into hundreds of thousand. This is where this covid treatment drug will greatly benefit along with some of the other approved Covid treatments
US efforts to boost biotech industry lead to China selloff
The latest US effort to reduce reliance on China is striking hard at the Asian nation’s biotech stocks, as investors price in more indications of decoupling between the world’s two biggest economies.
Following US President Joe Biden’s executive order to bolster domestic bio-manufacturing and cut reliance on foreign companies, bellwether Chinese stocks such as $WUXI BIO(02269.HK$ Wuxi Biologics Cayman Inc. and $WUXI APPTEC(02359.HK$ WuXi AppT...
Following US President Joe Biden’s executive order to bolster domestic bio-manufacturing and cut reliance on foreign companies, bellwether Chinese stocks such as $WUXI BIO(02269.HK$ Wuxi Biologics Cayman Inc. and $WUXI APPTEC(02359.HK$ WuXi AppT...
5
1
$KINTOR PHARMA-B(09939.HK$
Kintor soared on news of Covid-19 drug efficacy.
Kintor soared on news of Covid-19 drug efficacy.
1
Hang Seng pharmaceuticals sector slumps more than 6%, Kintor Pharma falls 20%, Fosun Pharma down 16% as investors cheer Merck's antiviral pill.
$Pharmaceuticals(BK1067.HK$
$FOSUN INTL(00656.HK$
$KINTOR PHARMA-B(09939.HK$
$Pharmaceuticals(BK1067.HK$
$FOSUN INTL(00656.HK$
$KINTOR PHARMA-B(09939.HK$
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg